U.S. Markets open in 1 hr 17 mins

Rosetta Genomics Ltd. (ROSG)

NASDAQ Capital Market - NASDAQ Capital Market Delayed Price. Currency in USD
Add to watchlist
1.65+0.02 (+1.23%)
At close: 3:54PM EDT
People also watch
RXIIPSTICLSNCYCCOPXA
  • P
    Pharmaherooooooo
    Pharmaherooooooo

    SLNO (MC $18 M) BLOCKBUSTER in Phase 3 /Rare Disease & Orphan Status = REAL Unknown low float stock with 1000% upside Potential and more .Next billion dollar rare disease company like SRPT here .GLTA

    Soleno therapeutics (SLNO)

    Market Cap $18 Million
    Cash: $8 Million
    Price $0.37

    Shares Out: 47.6 Million ( 36 Million shares held by Insiders & Institutions)

    Initiating Coverage June 26, 2017
    http://www.lifescicapital.com/wp-content/uploads/Soleno.pdf

    •Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete

    Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.

    Market Opportunity for PWS is Substantial.

    While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE)
    Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.

  • J
    Justin
    Justin
    guess revenues haven't been that great for the first half of the year, which is probably why Kenney is scared to report earnings. what does this PR mean for long investors? Nothing given the history of Kenny' s lies. sure it sounds great but will anytj ing come from it?
    Major Clinical Reference Laboratory Selects RosettaGX Reveal Thyroid miRNA Classifier as Molecular Test of Choice
    Laboratory's Entire Sales Team to Promote Reveal to All its Customers Throughout the Southwestern United States PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / August 21, 2017 / Rosetta Genomics Ltd. ...
    finance.yahoo.com
  • m
    michael
    michael
    more great news. with a partner that wont let ken to use their name...great job ken..more niothing
  • J
    Justin
    Justin
    Kenny diluting more next month and no word of any earnings... what a #$%$ bag!
  • T
    Tyler
    Tyler

    Found a great no fee daytrading newsletter, vist www.T0pm@rketgainers.c0m and sign up...so glad I did.

  • n
    nick
    nick
    Any Palestinians invest in this? You're closer than we are.. if u know what I mean.. I didn't lose much on this but I'm sorry for those that did. 400K a year goes to the CEO with probably the worst performing stock ever in the Nasdaq? What a Jew scam artists.
  • G
    Gannon
    Gannon
    Largest Galners 0n the NASDAQ & NYSE ---> T0pMarketGalners.c0m
  • J
    Jake
    Jake
    Do you understand that no one buys their tests? There are so many other better run companies that sell these type of tests. I told you long ago that this company will shut its doors. It is a joke. Last cash grab before out of business. You should not buy this trash.
  • J
    Jake
    Jake
    Been saying this for a long time, Kenny is a con artist and he is scamming people!
  • M
    Mark
    Mark
    Shares have to be above $1.50 for these investors to sell, right?
  • L
    Littleguy
    Littleguy
    At the current market price, Berlin would have to increase the number of shares by 50% just to get the market cap back to where it was a week ago. This is like adding water to a thin soup: you have more to serve, but there's not much taste or nutrition in every spoonful.
  • L
    Littleguy
    Littleguy
    Once again, current shareholders are screwed. Berlin said not long ago that they would look to add capital through some other way than by issuing more shares. Price rose to $2.60. Now they price a secondary at 1.50 with warrants to buy at 1.40. So, the new share holders sell all of their shares at any price above 1.50 and hold onto the warrants in case price actually does go up. They have no cash investment (i.e. no downside risk) and the chance to make some money if ROSG finds a cure for stupid management.
  • L
    Littleguy
    Littleguy
    Earnings are going to be released in the next couple of weeks. Bet ya that losses are at least half of the cash generated by this secondary. I doubt that revenue will be even half of the amount of the secondary offering.
  • m
    michael
    michael
    deal done under 1 dollar. raise 3m bucks...dilution 80percent of the company...insane...worst mgmt and board in history...all should be barred from working for public companies
  • b
    blue
    blue
    gedy for ascary scary crash crashbelow 1.50 be veryvery af money run run to the exit exit door get ouout beterbesafe than sorry
  • m
    michael
    michael
    only abke to raise 3m bucks. so sad. sub 1 next 30 days
  • L
    Littleguy
    Littleguy
    When, if ever, has a management action resulted in a higher stock price? It seems to me that any rise in share price is an invitation by management to bring it back down.
  • n
    nick
    nick
    Has anyone tried actually suing this company before, just curious? I'm in on small shares but jeez I have never, ever seen this thing going up. Where are the lawsuits?
  • J
    Jake
    Jake
    When the pumpers came in last couple of weeks, I knew that this was going to take a chtz! Shorts love this stock! Ken Berlin will be looking over his shoulder for the rest of his life, FBI, etc; all for greed!
  • L
    Littleguy
    Littleguy
    10% of market cap. Last I read, Ken's annual salary is $500K. That's over 10% of market cap. Imagine if any other CEO were paid that much. #$%$ company with stinking leadership.